These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37705084)

  • 1. N-acetylglucosamine inhibits inflammation and neurodegeneration markers in multiple sclerosis: a mechanistic trial.
    Sy M; Newton BL; Pawling J; Hayama KL; Cordon A; Yu Z; Kuhle J; Dennis JW; Brandt AU; Demetriou M
    J Neuroinflammation; 2023 Sep; 20(1):209. PubMed ID: 37705084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of a Marker of N-Acetylglucosamine With Progressive Multiple Sclerosis and Neurodegeneration.
    Brandt AU; Sy M; Bellmann-Strobl J; Newton BL; Pawling J; Zimmermann HG; Yu Z; Chien C; Dörr J; Wuerfel JT; Dennis JW; Paul F; Demetriou M
    JAMA Neurol; 2021 Jul; 78(7):842-852. PubMed ID: 33970182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-acetylglucosamine drives myelination by triggering oligodendrocyte precursor cell differentiation.
    Sy M; Brandt AU; Lee SU; Newton BL; Pawling J; Golzar A; Rahman AMA; Yu Z; Cooper G; Scheel M; Paul F; Dennis JW; Demetriou M
    J Biol Chem; 2020 Dec; 295(51):17413-17424. PubMed ID: 33453988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-acetylglucosamine inhibits T-helper 1 (Th1)/T-helper 17 (Th17) cell responses and treats experimental autoimmune encephalomyelitis.
    Grigorian A; Araujo L; Naidu NN; Place DJ; Choudhury B; Demetriou M
    J Biol Chem; 2011 Nov; 286(46):40133-41. PubMed ID: 21965673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing cell permeability of N-acetylglucosamine via 6-acetylation enhances capacity to suppress T-helper 1 (TH1)/TH17 responses and autoimmunity.
    Lee SU; Li CF; Mortales CL; Pawling J; Dennis JW; Grigorian A; Demetriou M
    PLoS One; 2019; 14(3):e0214253. PubMed ID: 30913278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuronal injury in chronic CNS inflammation.
    Zindler E; Zipp F
    Best Pract Res Clin Anaesthesiol; 2010 Dec; 24(4):551-62. PubMed ID: 21619866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-glycan processing deficiency promotes spontaneous inflammatory demyelination and neurodegeneration.
    Lee SU; Grigorian A; Pawling J; Chen IJ; Gao G; Mozaffar T; McKerlie C; Demetriou M
    J Biol Chem; 2007 Nov; 282(46):33725-33734. PubMed ID: 17855338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-corrected neurofilament light chain ratio decreases but does not predict relapse in highly active multiple sclerosis patients initiating natalizumab treatment.
    Højsgaard Chow H; Petersen ER; Olsson A; Hejgaard Laursen J; Bredahl Hansen M; Oturai AB; Soelberg Sørensen P; Bach Søndergaard H; Sellebjerg F
    Mult Scler Relat Disord; 2024 Aug; 88():105701. PubMed ID: 38889559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of interferon and glatiramer acetate on cytokine patterns in multiple sclerosis patients.
    Ganji A; Monfared ME; Shapoori S; Nourbakhsh P; Ghazavi A; Ghasami K; Mosayebi G
    Cytokine; 2020 Feb; 126():154911. PubMed ID: 31731047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis.
    Link J
    Acta Neurol Scand Suppl; 1994; 158():1-58. PubMed ID: 7732782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis.
    Barro C; Healy BC; Liu Y; Saxena S; Paul A; Polgar-Turcsanyi M; Guttmann CRG; Bakshi R; Kropshofer H; Weiner HL; Chitnis T
    Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36376097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.
    Ludwig MD; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2018 Feb; 243(4):361-369. PubMed ID: 29307283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a novel orally administered calpain inhibitor SNJ-1945 on immunomodulation and neurodegeneration in a murine model of multiple sclerosis.
    Trager N; Smith A; Wallace Iv G; Azuma M; Inoue J; Beeson C; Haque A; Banik NL
    J Neurochem; 2014 Jul; 130(2):268-79. PubMed ID: 24447070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in serum levels of IL-17 in contrast to TNF-alpha correspond to disease-modifying treatment in relapsing-remitting multiple sclerosis.
    Trenova AG; Slavov GS; Manova MG; Draganaova-Filipova MN; Mateva NG; Miteva LD; Stanilova SA
    Scand J Clin Lab Invest; 2017 Jul; 77(4):283-288. PubMed ID: 28319417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Neurofilament Identifies Patients With Multiple Sclerosis With Severe Focal Axonal Damage in a 6-Year Longitudinal Cohort.
    Steffen F; Uphaus T; Ripfel N; Fleischer V; Schraad M; Gonzalez-Escamilla G; Engel S; Groppa S; Zipp F; Bittner S
    Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36411080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum neurofilament light chains in progressive multiple sclerosis patients treated with repeated cycles of high-dose intravenous steroids.
    Stork L; Haupts M; Kruse N; Spill-Askeridis P; Kutllovci A; Weber MS; Brück W; Metz I
    Free Neuropathol; 2023 Jan; 4():. PubMed ID: 37859628
    [No Abstract]   [Full Text] [Related]  

  • 18. Rituximab for people with multiple sclerosis.
    Filippini G; Kruja J; Del Giovane C
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013874. PubMed ID: 34748215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis.
    Maggi P; Kuhle J; Schädelin S; van der Meer F; Weigel M; Galbusera R; Mathias A; Lu PJ; Rahmanzadeh R; Benkert P; La Rosa F; Bach Cuadra M; Sati P; Théaudin M; Pot C; van Pesch V; Leppert D; Stadelmann C; Kappos L; Du Pasquier R; Reich DS; Absinta M; Granziera C
    Neurology; 2021 Aug; 97(6):e543-e553. PubMed ID: 34088875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High or increasing serum NfL is predictive of impending multiple sclerosis relapses.
    Thebault S; Reaume M; Marrie RA; Marriott JJ; Furlan R; Laroni A; Booth RA; Uccelli A; Freedman MS
    Mult Scler Relat Disord; 2022 Mar; 59():103535. PubMed ID: 35078125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.